NCT04963270 2025-02-28A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisHoffmann-La RochePhase 3 Terminated188 enrolled 40 charts
NCT05218096 2025-01-09Study of ALXN2050 in Adult Participants With Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.Phase 2 Terminated70 enrolled 14 charts
NCT03579966 2024-05-07Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)Catalyst Pharmaceuticals, Inc.Phase 3 Terminated63 enrolled 10 charts
NCT03896295 2023-06-27An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia GravisMomenta Pharmaceuticals, Inc.Phase 2 Terminated37 enrolled 40 charts
NCT00727194 2019-09-24Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.Phase 2 Terminated14 enrolled 23 charts
NCT00424489 2018-08-31Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia GravisNorthwestern UniversityPhase 1 Terminated9 enrolled 8 charts